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Classification, pathophysiology and diagnosis of thalassaemia are 
discussed in part 1[1] of this 2-part CME series. The current article 
(part 2) discusses management aspects relating to the three clinical 
phenotypes, viz.: (i) thalassaemia major (TM), also referred to as 
transfusion-dependent thalassaemia (TDT); (ii) thalassaemia intermedia 
(TI), which is generally transfusion independent; and (iii) thalassaemia 
minor, which is asymptomatic, with no significant clinical sequelae.
Thalassaemia major
The management of TDT major requires appropriate transfusion 
therapy, frequent monitoring to assess iron overload, and treatment 
with focused chelation therapy. With these in place, patients will 
survive longer, without the morbidity of complications due to 
inadequate chelation. Transfused blood contains iron (Fe), which the 
body is unable to excrete. Regularly transfused patients accumulate 
iron at a rate of 0.3 - 0.6 mg/kg of body weight per day.[2] Once iron 
is >12 - 24 g of total body iron, it accumulates in the heart, liver and 
endocrine system.
Blood transfusion
Once the diagnosis has been made, the infant needs to be monitored 
clinically with regular full blood counts (FBC). 
The decision to commence regular transfusions[2] is based on the 
following criteria: 
• A haemoglobin (Hb) level <7  g/dL on two occasions, >2 weeks 
apart (excluding all other contributory causes such as infections); 
or
• A steady state Hb <7 g/dL with any one of the following: 
• failure to thrive
• bone expansion or deformity, especially facial bones
• inappropriate fatigue
• poor feeding
• developmental delay or regression
• cardiac failure
• increasing splenomegaly
• In most cases, it may be reasonable to administer the first transfusion, 
then wait and re-assess the indications and trends before the second 
and subsequent transfusions.
• Patients with TI should not receive regular transfusion therapy unless 
indicated. The diagnosis of TI and TM is not always absolute or 
predictable, and a period of watching and waiting may be necessary. 
Before starting blood transfusions, baseline tests need to be 
performed, which includes an FBC, red cell phenotype, liver function 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
Thalassaemia (part 2): Management
N A Alli,1 MB BCh, FCPath Haem (SA); M Patel,2 MB ChB, FCP (SA), MMed (Int Med), FRCP (London), PhD; J Poole,3 MB BCh, 
DCH (SA), FCP (SA) Paed; Y Goga,4 MB BCh, DCH (SA), FCPaeds (SA), Cert Clin Haem Paed (SA), MSc Bioethics, PG Dip Paed Pall Medicine;  
F Fazel,5 MB BCh, FCP (SA), MMed (Int Med), Cert Clin Haem (SA); N Novitzky,6 Dip Med, PhD;      
S Parasnath,7 MB ChB, FCPath (SA), Cert Clin Haem (SA); F Bassa,6 MB ChB , FCPath Haem (SA), MMed (Haem)
1  Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory 
Service, Johannesburg, South Africa
2  Department of Medicine, Chris Hani Baragwanath Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, 
Johannesburg, South Africa
3  Department of Paediatrics and Child Health, Paediatric Haematology/Oncology Unit, Faculty of Health Sciences, University of the Witwatersrand 
and Charlotte Maxeke Hospital, Johannesburg, South Africa
4  Department of Paediatrics and Child Health, Nelson R Mandela School of Medicine, University of KwaZulu-Natal and Inkosi Albert Luthuli 
Central Hospital, Durban, South Africa
5  Division of Clinical Haematology, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Tygerberg Academic Hospital and 
Stellenbosch University, Cape Town, South Africa
6 Blood Centre, Rondebosch Medical Centre, Cape Town, South Africa
7  Department of Clinical Haematology, Inkosi Albert Luthuli Central Hospital and Nelson R Mandela School of Medicine, University of KwaZulu-
Natal, Durban, South Africa
Corresponding author: N A Alli (nazeer.alli@nhls.ac.za) 
The management of thalassaemia with a severe phenotype includes blood transfusion, iron chelation, bone marrow transplantation, prenatal 
diagnosis and national programmes to co-ordinate these in countries with a high prevalence. If blood transfusion and iron chelation therapy 
are not administered regularly, as was the case historically and as is still the case in many poorer regions, progressive deterioration occurs, 
viz. impaired growth and development, hepatosplenomegaly, bony abnormalities, cardiac failure, increased susceptibility to infections 
and premature mortality. Remarkable progress has been made in the past few decades, which has led to much-improved survival rates. 
Transfusion therapy has evolved to a hyper-transfusion regimen designed to maintain a physiological haemoglobin level and achieve a post-
transfusion haemoglobin of 14 g/dL, which, as a matter of course, necessitated intensification of iron chelation. The development of effective 
oral iron chelators has led to improved compliance. Exploration of novel therapeutic approaches continues, with several agents under study. 
The prospect of gene therapy is particularly exciting as it has potential to provide cure on a large scale. Currently, regular blood transfusion 
and iron chelation therapy remain the cornerstone of management of thalassaemia major.
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tests (LFTs), serum iron studies, serum ferritin and baseline viral 
determination for hepatitis B (HBV), hepatitis C (HCV), HIV, 
cytomegalovirus (CMV) and parvovirus B19. Regular follow-up with 
blood tests at selected intervals is important for early identification of 
complications (Table 1).
Transfusion programme 
Transfusion therapy aims to permit normal growth and activity 
levels, and prevent skeletal changes due to marrow hypertrophy. 
Transfusions should initially be given every 3 - 5 weeks.[3]
The pre-transfusion Hb determines the volume of blood to be 
transfused, and the aim is to maintain the pre-transfusion Hb 
between 9 g/dL and 10.5 g/dL.
In paediatric patients, transfusion volume (mL) = (target Hb 
14 g/dL – actual Hb) × weight (kg) × 3.5. The post-transfusion Hb 
should not exceed 14 g/dL. Blood should be transfused at a rate of 
5 mL/kg/hour.
In patients with severe anaemia (Hb <5  g/dL) or those with 
cardiac compromise, transfusions should be administered at 
2  mL/kg/h to avoid fluid overload. Diuretics may need to be 
administered.
If cardiac insufficiency is present, pre-transfusion Hb levels need to 
be maintained at higher levels, i.e. between 11 g/dL and 12 g/dL, and 
small volume transfusions may need to be administered weekly or 
every 2 weeks.
Transfusion volume should be recorded at each visit, and the 
transfusion requirements reviewed 6 - 12-monthly. The usual transfusion 
requirement is between 200 mL/kg/year and 250 mL/kg/year.
Ideally, the type of blood product to be used is leukodepleted 
packed red cells, preferably <5 days old. Some blood banks can supply 
highly packed red cells by a process of spinning and aspirating excess 
plasma.
Blood transfusions should be given in a dedicated facility, and 
administered with minimal disruption to the patient, to maintain 
good quality of life. Good transfusion practice should be observed 
with written policies (standard operating procedure).
Iron overload and chelation therapy 
Regularly transfused patients accumulate iron at a rate of 0.3 - 
0.6 mg/kg of body weight per day.[2] The human body does not have a 
physiological mechanism to excrete iron. When total body iron exceeds 
12 - 24 g, it accumulates in the heart, liver and endocrine system.
Table 1. Schedule of measurements and follow-up assessments
Test Age, years Frequency 
FBC differential count and platelets 
LFTs
U&E, urine dipstix
All Monthly (or more frequently if indicated)
Monthly if on DFP or DFX
Monthly if on DFX
Ferritin All Every 3 months
Hepatitis B and C, HIV All Annual
FSH, LH ≥10 Annual. If abnormal, GnRH stimulation test, where 
indicated










Fasting/random glucose ≥10 Every 6 months. OGTT if abnormal
α FP/liver ultrasound ≥10 Annual
FerriScan (MRI R2)











10 - 20 ms: annually
<10 ms: 6 monthly
Bone mineral density scan/DEXA ≥10 Every 18 - 24 months
Tanner stage 10 - 20 Every 6 months
Anthropometrics (height, truncal height, weight, head 
circumference,  growth velocity)
All Annual, every 3 - 6 months, during puberty and chronic 
transfusion, as indicated
Menstrual history and reproductive health ≥10 or 
earlier
Annual
Transfusion history All Monthly or more frequently if indicated
Chelation history and toxicity monitoring All Annual
Reproductive health ≥12 Annual
Dental assessments All Annual
Ocular and auditory assessments All Annual, once chelation commenced 
Genotype All Once
Transplant evaluation/HLA typing All Once
FBC = full blood count; LFT = liver function test;  DFP =  deferiprone; DFX = deferasirox; U&E = urea and electrolytes; FSH = follicle-stimulating hormone; LH =  luteinising hormone; 
GnRH = gonadotrophin releasing hormone; PTH = parathyroid hormone; TSH = thyroid stimulating hormone; T4 =  thyroxine; OGTT = oral glucose tolerance test;  α FP = alpha feto-protein; 
MRI = magnetic resonance imaging; TRV = tricuspid valve regurgitant velocity; DEXA = dual energy X-ray absorptiometry; HLA = human leukocyte antigen. 
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Iron is extremely toxic to many tissues. Excess iron that exists as non-
transferrin bound iron (NTBI) in the plasma and unbound iron in 
the intra-cellular compartment results in free radical damage to cells. 
It takes 3 - 10 years of chronic exposure to high iron levels before any 
measurable organ dysfunction occurs. Each organ has a different rate 
of iron deposition and reduction.[2-9] 
The most effective strategy to prevent significant iron overload and 
tissue damage is early institution of chelation therapy, i.e. as soon as 
the patient is iron-overloaded.
Chelation therapy has two goals: (i) binding of toxic NTBI in the 
plasma; and (ii) removal of iron from the body.
Since removal of iron from normal tissues can be detrimental, 
chelation should not be started without evidence of iron overload. 
In infants, chelation therapy should be delayed until after the 
first year of life due to the toxicity of the chelators. It is generally 
commenced after 10 - 12  transfusions, or when the ferritin 
is persistently >1 000  µg/L. First-line therapy is usually oral 
deferasirox (DFX), which can be commenced in an infant >1 year 
of age. Subcutaneous administration of desferrioxamine (DFO) is 
an alternative but more traumatic for both patients and parents/
caregivers, given the parenteral route of administration and longer 
duration of administration.
The aims of iron chelation therapy are:[2-9]
(i)  to prevent iron overload and maintain a safe level of body iron 
by balancing iron intake from transfusion with iron excretion 
through chelation.
(ii)  rescue therapy: once excess iron accumulates in organs, damage 
starts to occur. Removal of iron is slow and inefficient, therefore 
prevention is superior to rescue therapy. 
(iii)  emergency therapy: if heart failure develops, this requires urgent 
modification of chelation therapy with intensive treatment (see 
below).
There are currently three iron chelators available in South Africa 
(SA), viz. DFO mesylate (DFX) (Desferal), deferasirox (Exjade) 
and deferiprone (DFP)(Ferriprox). DFP availability is limited, and 
it currently requires a section 21 application via the SA Health 
Products Regulatory Authority. Characteristics of each iron chelator 
are detailed in Table 2.
All chelation regimens aim to attain and maintain an annual 
average serum ferritin of 500 µg/L - 1 000 µg/L, a liver iron between 
3 mg/g and 7 mg/g dry weight (dw) and cardiac T2* >20 ms2. 
The selection of drugs and doses will require adjustments 
depending on the iron burden and drug toxicities (Fig. 1).
Table 2. Characteristics of the available iron chelators
Characteristic Desferrioxamine (Desferal) Deferasirox (Exjade) Deferiprone (Ferriprox)
Usual dose Children: 20 - 40 mg/kg/day
Adults: 20 - 60 mg/kg/day
20 - 40 mg/kg/day 75 - 100 mg/kg/day, in three 
divided doses
Route and frequency SC or IV
SC: over 8 - 10 hours per night, for 5 - 7 
nights per week
Oral: daily (on empty stomach/ 
preprandial) 
Oral: every 8 hours
Half-life 20 - 30 min 8 - 16 hours 3 - 4 hours
Route of excretion Urinary, faecal Faecal Urinary, some faecal
Iron chelating ability High (hexadentate) Moderate (tridentate) Low (bidentate)
Lipid solubility Low High Intermediate 
Monitoring Annual: ocular and auditory assessment Annual: ocular and auditory 
assessment
Monthly: urinalysis, U&E, LFT
3-monthly: FBC
Annual: ocular and auditory 
assessment
Weekly FBC, then 2-weekly or 
monthly
Side-effects Skin reactions at injection site 
Hypersensitivity
Bone changes, growth retardation,     
vertebral dysplasia, genu-valgum
High-tone sensorineural deafness, tinnitus
Visual changes: cataracts and retinopathy
Growth retardation




GIT: abdominal pain, diarrhoea, 
nausea, vomiting
Renal: raised creatinine 
(non-progressive, reversible), 
proteinuria




Mild to severe neutropenia/ 
agranulocytosis                   
GIT: abdominal discomfort
Abnormal liver function tests 
(transaminitis)        
Arthralgia/arthritis        
Zinc deficiency              
Increased appetite       
Teratogenic 
Advantages Long-term experience
Safe in children <2 years
Intensive therapy reverses liver and cardiac 
overload
May be combined with deferiprone for 
severe cardiac Fe overload
Oral
Safe in children from 1 to 2 years 
of age
Long half-life, allows daily dosing
Better compliance
Oral
More effective in removing cardiac 
iron
Disadvantages Prolonged parenteral infusions
Poor compliance
Bone toxicity and negative growth effects
Limited long-term safety data Agranulocytosis, requires close 
monitoring
SC = subcutaneous; IV = intravenous; U&E = urea and electrolytes; LFT = liver function test; FBC = full blood count; GIT = gastrointestinal tract; ALT = alanine transaminase; Fe = iron.
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Iron overload needs to be monitored 
regularly. Direct measurement of liver iron 
concentration via liver biopsy is invasive.
The following are methods of indirect 
measurement of tissue iron stores: 
• serum ferritin
• magnetic resonance imaging (MRI) T2* 
for cardiac iron assessment
• MRI R2 (FerriScan) for liver iron 
assessment.
Serum ferritin is simple to perform, 
inexpensive and widely available. It is most 
useful in identifying trends. Levels should 
be monitored 3-monthly after the first 10 
transfusions. Decisions to modify dosages 
should be based on serial measurements 
of ferritin as opposed to a single reading. 
Persistently high levels >2 500  ug/L are 
associated with increased risk of cardiac 
disease and death. Ferritin levels correlate well 
with liver iron levels in a linear fashion, but do 
not always correlate well with myocardial iron 
deposition, as patients with low ferritin levels 
may have severe cardiac iron loading and left 
ventricular (LV) impairment.
Liver iron: The R2 technique (FerriScan) can 
be performed on a standard MRI machine, 
but the analysis requires specific software. 
The advantage of the T2* technique is that 
liver and cardiac iron can be measured 
at the same time. The target should be 
3 - 7  mg/g dw equivalent measured by the 
FerriScan technique. Liver iron >7 mg/g dw 
is associated with increased complications, 
including a higher risk of cardiac disease and 
early death.
Cardiac iron: The best available method 
for the measurement of cardiac iron is the 
cardiac MRI T2*. There is a relationship 
between low T2* and impaired LV function. 
LV impairment becomes increasingly likely 
when T2* falls below 20 ms, and is therefore 
used as a cut-off for the early detection of iron 
overload.
Cardiac MRI T2* and the FerriScan are 
recommended for routine monitoring in 
children from age ≥10 years. The intervals of 
the scans depend on whether the results are 
abnormal or normal (Fig. 1).
Chelation therapy needs to be modified 
when there is evidence of severe iron 
overload and/or organ dysfunction. 
This may be achieved with the following 
strategies:
(i)  Combination therapy:[2] combination 
treatment with DFO and DFP has 
been shown to be more effective than 
DFO monotherapy in: a) reducing 
serum ferritin; b) reducing liver 
iron; c)  improving cardiac function; 
d)  reversing cardiac failure; and 
e) reversing impaired glucose tolerance.
(ii)  Optimising dosing or switching of 
preparations.
(iii)  Intensive intravenous chelation with 
continuous high-dose DFO: this is used 
when aggressive chelation is required 
with severe iron overload and cardiac or 
liver dysfunction. This can be given twice 
a month for a minimum of 72  hours at 
a maximum dose of 6  g/kg/day, and is 
given in addition to the regular chelation 
therapy.
Chelation therapy also needs to be modified 
if body iron falls or reaches low levels, and 
doses need to be adjusted to prevent toxicity. 
Doses should be gradually decreased when 
the serum ferritin falls below 1 000  µg/L. 
Although the current recommendation 
is to stop the drug when the ferritin is 
<500  µg/L, one must be cautious, as this 
may result in rebound labile iron. This 
can be avoided by gradual dose reductions 
coupled with more intensive monitoring 
(monthly ferritin levels) to maintain the 
ferritin between 500 µg/L and 1 000 µg/L.
Commence transfusion
Measure serum ferritin 
after 10 - 12 transfusions
Ferritin 1 000 - 2 500 µg/L, 
LIC 7 - 15 mg Fe/g dry weight, or 
cardiac T2* 10 - 20 ms
Monitor iron overload 
• serum ferritin every 3 months
• FerriScan annually from age 10 years*
• MRI T2* annually from age 10 years
Assess cardiac function
If abnormal cardiac function
If normal cardiac function, 
optimise chelation
• increase DFX to 40 mg/kg/d, or
• increased DFP to 100 mg/kg/d*
Review in 6 months
3 - 4-weekly transfusions
Maintain pre-transfusion 
Hb at 9 - 10.5 g/dL
Commence chelation if ferritin 
persistently >1 000 µg/L
Age >1 year: DFX (Exjade) 20 - 30 mg/kg orally as rst line
OR
DFO (Desferal) 20 - 40 mg/kg, SC over 8 - 10 hours, 5 days per week
Intensive therapy with
• DFO IV 50 mg/kg/24 h, or
• change to DFP*, or
• consider combination therapy with 
  DFO and DFP*
Ferritin >2 500 µg/L, 
LIC >15 mg Fe/g dry weight,
cardiac T2* <10 ms, or
abnormal cardiac function
Fig. 1. Algorithm for optimal monitoring of iron accumulation and chelation. (Hb = haemoglobin; 
DFX = deferisirox; DFO = desferrioxamine; SC = subcutaneous; MRI = magnetic resonance imaging; 
LIC = liver iron concentration; Fe = iron; DFP = deferiprone; IV = intravenous.)
*if available.
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Management of complications
Iron overload is the major cause of morbidity and mortality in 
TM/TI, and occurs rapidly in patients on a chronic transfusion 
programme. Most deaths occur due to iron-related cardiomyopathy. 
Cardiac iron loading takes 8 - 10 years to develop, and the heart is 
initially devoid of iron for years. Once iron loading in the heart starts, 
the rate of deposition is rapid. 
Iron overload also affects the liver, resulting in cirrhosis and liver 
failure. Iron deposition in the liver occurs in a linear fashion, and 
significant iron loading ensues after 6 months of regular transfusions. 
Pancreatic, thyroid, parathyroid, hypothalamic and pituitary damage 
may result in endocrinopathies.
Hepatic complications 
Liver disease in thalassaemia is common, and frequently multi-
factorial.[10] The liver is a primary site of iron overloading, and is 
one of the leading causes of mortality in TDT. Chronic liver iron 
deposition stimulates fibrogenesis and cirrhosis.[11]
Patients may present with acute or chronic hepatitis (viral 
or drug-induced), obstructive jaundice, cholangitis, portal 
hypertension, liver insufficiency or hepatocellular carcinoma. 
Chronic active HCV infection should be actively managed. The 
current recommended treatment for HCV is with a combination 
of pegylated interferon alpha and ribavirin. Ribavirin may result 
in haemolysis with increased transfusion requirements and iron 
chelation while on the drug. 
Serum ferritin and liver iron deposition have a good correlation. 
Assessment of liver iron was previously done via a direct measure 
of dry liver iron and required a needle biopsy or intraoperative 
wedge biopsy. This is invasive, and as liver iron deposition is 
patchy, the results are poorly reproducible. MRI is a sensitive 
measure of tissue iron levels and is a non-invasive alternative to 
biopsy. Liver iron should be assessed by R2 or T2* MRI annually. 
Aggressive intensification of chelation should be instituted if liver 
iron concentration is >7  mg/g dw. Regular screening for liver 
dysfunction is recommended (Table 2), which includes monthly 
LFTs if patients are on DFX or DFP. If the alanine transaminase 
is increased, it should be repeated after 2 weeks, and if it remains 
elevated, or is intermittently elevated over a 3-month period, a 
complete assessment for hepatitis would be indicated[12] viz., 
• international normalised ratio/partial thromboplastin time
• hepatitis A IgM
• hepatitis B DNA quantification
• hepatitis C Ab and polymerase chain reaction
• CMV serology, viral load and liver biopsy if the hepatitis C is 
positive
• ultrasound (US), computed tomography (CT) and endoscopic 
retrograde cholangio-pancreatogram (ERCP), as indicated. 
Hepatitis B vaccination should be given, and antibody titres checked 
annually to assess immune status. Booster vaccinations may be 
required (Table 3).
Liver complications should be managed in conjunction with a 
hepatologist.
Cardiovascular complications
Cardiac disease due to thalassaemia includes LV dysfunction, 
pulmonary hypertension and right ventricular (RV) dysfunction.[16] 
The mechanism of LV dysfunction includes a high-output cardiac 
state, iron overload, vascular disease, myocardial ischaemia and 
myocarditis.[6] Effective iron chelation reduces the risk of cardiac 
disease and improves survival. Cardiac iron overload develops 
from age 10 years in poorly chelated patients. Serum ferritin and 
liver iron concentration levels do not correlate well with cardiac 
iron overload.[16] Cardiac MRI T2* is the best available method 
for the detection of cardiac iron overload. There is a relationship 
between low T2* and impaired LV function. LV impairment becomes 
increasingly likely when T2* falls below 20 ms. 
T2* is used to monitor response to chelation, which should be 
adjusted as necessary. 
Early identification of cardiac abnormalities and prompt treatment, 
including aggressive chelation, can reverse cardiac damage. Small-
volume blood transfusions (to avoid fluid overload) given more 
frequently, such as fortnightly, may be needed. Higher target pre-
transfusion Hb level (10 - 12 g/dL) is recommended if there is cardiac 
dysfunction.[4]
Splenectomy, transfusion intensity (frequency and pre-transfusion 
Hb), history of thrombosis and severity of iron overload are the 
strongest predictors of pulmonary hypertension. These patients can 
be effectively managed by initiating regular transfusions to maintain 
a pre-transfusion Hb of 9.5  g/dL. Thromboprophylaxis should be 
considered in patients with severe pulmonary hypertension. 
Echocardiography and electrocardiograms (ECGs) should be 
performed annually from age 10 years. Patients with cardiac failure 
and arrhythmias require urgent cardiac assessment and management. 
If the tricuspid regurgitant velocity (TRV) is 2.5 - 3.2  m/s and 
asymptomatic, transfusions and iron chelation should be optimised, 
and hydroxyurea and anticoagulant therapy should be considered. 
TRV >3.2  m/s requires referral to the cardiologist for further 
management. 
Endocrine complications
Iron is commonly deposited in endocrine organs, and damage that 
occurs is usually irreversible. This may result in diabetes mellitus 
(DM), growth failure, hypothyroidism, hypoparathyroidism, delayed 
puberty, hypogonadism, gonadal failure and sterility, as well as 
osteopenia and osteoporosis. The pituitary gland is particularly 
sensitive to even modest iron overload, with short stature in poorly 
chelated patients presenting around age 10 years. Regular monitoring 
of endocrine function is important (Table 1). Growth retardation 
and skeletal changes may also ensue from DFO toxicity. Patients 
with a fall-off on growth curves, decreased height velocity or delayed 
bone age should be referred to an endocrinologist for assessment 
and management. Hormone replacement therapy is advised for 
adolescents with hypogonadism.[3]
Infections
Patients with iron overload are susceptible to infection with bacteria 
such as Yersinia enterocolitica and Vibrio vulnificus. Yersinia is a 
Gram-negative bacillus that causes severe infection and disseminated 
tissue sepsis. V. vulnificus is a Gram-negative bacillus that can cause 
severe endotoxaemia, and is associated with high mortality.[17]
Other bacteria such as Escherichia coli and Klebsiella pneumoniae 
also occur with increased frequency in the presence of iron overload.
Despite significant improvements in blood safety, there remains a 
risk of transfusion-transmitted infections (TTI). The four major TTIs 
are caused by HIV, HBV, HCV and syphilis. 
Routine paediatric vaccinations should be kept up to date, 
including the annual influenza vaccine. 
Bone complications
Bone disease in thalassaemia results from bone marrow expansion, 
iron overload, iron chelation, endocrine dysfunction and vitamin D, 
C and K and zinc deficiencies.
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The clinical presentation includes growth impairment, rickets-
like bony lesions, back pain, spinal deformities, signs of nerve 
compression, severe osteoporosis and fragility fractures. Long bones, 
especially the humeri, may be short, with loss of the concave profile, 
and signs of growth arrest.[18]
Timeous and adequate transfusion therapy will prevent irreversible 
bony abnormalities that occur due to bone marrow expansion, viz. 
dental abnormalities, malocclusion, recurrent sinusitis and increased 
susceptibility to fractures. 
Paediatric patients on DFO may develop rickets-like bony lesions 
and sclerotic lesions, severe epiphyseal dysplasia resulting in genu 
valgum or genu varum, short stature, truncal shortening and 
vertebral dysplasia.[18] These skeletal abnormalities are associated 
with early initiation of DFO or high doses of DFO in the presence 
of reduced iron stores. In the latter scenario, skeletal changes are 
preventable by using lower doses of DFO (20 - 30 mg/kg/d). Bony 
changes have not been associated with the oral iron chelators, such 
as DFP and DFX. However, DFP may result in arthropathy and is 
associated with bone mineralisation defects, hypercalciuria and 
nephrocalcinosis.
There is a high prevalence of vitamin D deficiency, and this may 
contribute to osteopenia. Vitamin D supplementation should be 
commenced when levels are suboptimal. Established osteoporosis in 
adults should be treated with bisphosphonates and managed by an 
endocrinologist. Zinc supplementation should be instituted in those 
with low zinc levels. 
Renal disease
Renal disease in thalassaemia is a less well-recognised complication, 
caused by the disease itself, as well as iron chelators. Manifestations 
include tubular dysfunction, glomerular dysfunction and resultant 
proteinuria, haematuria, nephrolithiasis and renal failure.[19] Up to 
60% of TDT patients develop tubular dysfunction, which is related 
to iron overload, chronic anaemia and DFO toxicity. A renal biopsy 
is invasive and risky; therefore, MRI is essential for non-invasive 
assessment of iron overload. There is also a significant correlation 
between serum ferritin and renal iron deposition. Splenectomy is an 
independent risk factor for tubular abnormalities. 
DFX is very lipophilic and thus enters the tubular cells to form a 
highly charged complex with iron, causing a proximal tubulopathy 
and Fanconi syndrome.[19]
Thromboembolic disease
TM may be considered a hypercoaguable state, resulting from 
abnormalities in platelets and pathological red cells, endothelial 
dysfunction, coagulation system abnormalities and the presence of 
microparticles. Splenectomy in patients >35 years of age, anaemia 
(Hb <9 g/dL) and iron overload all contribute to the hypercoagulable 
Table 3. Vaccination schedule[13-15]
a. In-hospital vaccination protocol:
Administer vaccination on the day of discharge, or day 14, whichever comes earlier
Pneumococcal 13-valent conjugate (Prevnar 13) 0.5 mL IM
Haemophilus influenza type b vaccine (Hib) 0.5 mL IM
Meningococcal protein-conjugate polysaccharide vaccine (Menactra) 0.5 mL IM
Meningococcal polysaccharide vaccine (Menomune) 0.5 mL IM 
b. Follow-up vaccination protocol:
2 months after the initial vaccination:
Pneumococcal polysaccharide (Pneumovax 23) 0.5 mL IM
Meningococcal vaccine (Menactra) 0.5 mL IM
Meningococcal polysaccharide vaccine 0.5 mL IM (>1 - 3 months after first dose)
c. Long-term follow-up:
Pneumovax 23, 0.5 mL IM, 5 years after first dose of Pneumovax
Menactra 0.5 mL IM recommended every 5 years
No additional haemophilus vaccine required
Seasonal influenza vaccine indicated annually
Exceptions: 
 Patients who have received the Pneumovax 23 vaccine in the past year should wait at least 1 year to receive the Prevnar 13 vaccine, followed 
by a second Pneumovax 23 vaccine at least 8 weeks later. 
 If 2 doses of the Pneumovax 23 vaccine have been given in the past year, Prevnar 13 should be given 1 year after the  last Pneumovax 23 vaccine.
If Prevnar 13 has been given to the patient previously, a Pneumovax 23 dose may be given 8 weeks after Prevnar 13
IM= intramuscular.
Table 4. Pre-pregnancy evaluations in thalassaemia major 
Heart ECG, cardiac echo, MRI T2*
Liver LFTs, ultrasound, FerriScan
Endocrine HbA1c, thyroid, parathyroid functions
Viral infections HBV, HCV, HIV, rubella
Bone health DEXA scan, vitamin D and calcium
Optimisation of lifestyle issues Stop smoking and alcohol consumption
Review of medication Hormone replacement therapy, bisphosphonates, hypoglycaemic agents, iron chelators
ECG = electrocardiogram; MRI = magnetic resonance imaging; LFT = liver function test; HBV = hepatitis B virus; HCV = hepatitis C virus; DEXA = dual energy X-ray absorptiometry.
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state. Patients should be treated according to standard local 
thrombosis management guidelines.
Splenectomy in TM 
(see appendix 1: http://samj.org.za/public/sup/15898.pdf).
Thalassaemia in pregnancy 
(see appendix 2: http://samj.org.za/public/sup/15898.pdf).
Supportive care[3]
Psychological support
Thalassaemia patients and their parents require strong social circles 
and regular psychological support through various stages of the 
disease, including diagnosis, initiation of transfusion and iron 
chelation, and transition to self-care.
Psychosocial factors strongly influence adherence to treatment 
and can also predispose to illnesses such as depression. Ongoing 
support and encouragement by a multidisciplinary team including 
a psychologist and social worker are essential to ensure continued 
adherence to treatment and to address any psychosocial issues.
Dental care
Patients with thalassaemia are vulnerable to many dental complications, 
including malocclusion, an increased risk of dental caries and 
periodontal disease. Regular dental follow-up is necessary.
Lifestyle and quality-of-life issues
With increasing life expectancy of thalassaemia patients, healthcare 
providers should try their best to ensure that the disease and its 
treatment cause the least amount of disruption as possible to patients’ 
daily lives. Clinic appointments and transfusion regimens should be 
arranged in such a way that they have minimal impact on school or 
work activities.
Physical activity and sport should be encouraged, bearing in mind 
limitations due to anaemia and cardiopulmonary complications of the 
disease. 
Attention to adequate nutrition includes monitoring for zinc and 
vitamin D deficiency and encouraging a diet rich in calcium and 
vitamin E. L-carnitine supplements may have beneficial antioxidant 
and cardioprotective effects.
Education, prevention and counselling
Patients need to be provided with age-appropriate information and 
educational tools regarding their disease, its complications and 
treatment. 
Genetic counselling 
This should be available for couples who wish to have a child, and 
options for prenatal diagnosis must also be discussed.
Transition to adult care
Transition to self-care and adult clinics coincides with adolescence. 
This is a period when patients will challenge boundaries, and 
adherence is compromised. The transition must be gradual, and only 
when the patient is emotionally ready. Holding joint paediatric and 
adult outpatient clinics allows for a smoother transition to adult care, 
and is less intimidating to the patient.
Novel therapeutic approaches 
New therapeutic strategies aimed at improving the quality of life and 
improving outcomes are evolving as a result of improved understanding 
of the pathophysiology of β-thalassaemia. These include the following:
Addressing ineffective erythropoiesis
Growth differentiation factor 11 (GDF-11): this is overexpressed 
in immature erythroblasts in β-thalassaemia and induces 
expansion of erythroid progenitors with consequent ineffective 
erythropoiesis.[20] Novel strategies to bind/trap GDF11 include 
sotatercept and luspatercept.
In the BELIEVE trial studying the use of luspatercept, 21% of adults 
showed a 33% reduction in transfusion requirements, compared with 
4.5% on placebo.[20,21] 
Janus kinase 2 (JAK2) inhibitors: preclinical studies of JAK2 
inhibition in mouse models showed improvement in ineffective 
erythropoiesis and a decrease in splenomegaly, suggesting that the use 
of ruxolitinib (a JAK1/JAK2 inhibitor) could benefit β-thalassaemia 
patients.[22,23] The TRUTH Study in TDT showed a decrease in spleen 
size but no clinically significant improvements in pre-transfusion Hb, 
hence did not proceed into a phase III study.[24]
Improving iron overload
Minihepcidins: hepcidin is known to prevent iron utilisation and 
absorption. Preclinical studies propose that minihepcidins could 
restrict iron absorption and may be useful in addressing iron overload 
and improve ineffective erythropoiesis, anaemia and splenomegaly.[22,24] 
Transmembrane protease serine 6 (TMPRSS6) inhibitors: TMPRSS6, 
a transmembrane serine protease produced by hepatocytes, negatively 
regulates hepcidin expression (by cleaving haemojuvelin) and is thus 
an important modulator of hepcidin expression. 
Manipulation of ferroportin inhibitors and HIF2α: ferroportin plays 
a crucial role in iron homeostasis by exporting iron from enterocytes 
to the circulation. Intestinal HIF2α (hypoxia-inducible factor-2α) 
regulates ferroportin expression in response to changes in systemic 
iron requirements.[22]
Haemoglobin F (fetal haemoglobin) inducers
Haemoglobin F inducers include: (i) DNA methylation inhibitors, 
such as 5-azacytidine and decitabine; (ii) hydroxyurea; and (iii) short-
chain fatty acids.
Bone marrow transplantation 
(see appendix 3: http://samj.org.za/public/sup/15898.pdf).
Gene therapy 
(see appendix 4: http://samj.org.za/public/sup/15898.pdf).
Thalassaemia intermedia
TI or non-transfusion dependent thalassaemia (NTDT) refers to the 
clinical phenotype of thalassaemia where patients do not require 
regular lifelong blood transfusions for survival.[25] This group includes 
α-thalassaemia intermedia (HbH disease), β-thalassaemia intermedia 
and mild to moderate forms of HbE/β-thalassaemia.[26] 
Patients with TI present with anaemia with varying degrees 
of severity. Ineffective erythropoiesis, chronic anaemia and iron 
overload can lead to more severe clinical complications in TI than 
in a routinely transfused, well-chelated patient with β-thalassaemia 
major[27] (see Table 3, part 1, CME[1] for clinical complications of 
thalassaemia).
Patients with TI should be on routine folic acid supplementation. 
The specific management of patients with TI includes conventional 
modalities, novel agents and stem cell transplantation.
Transfusion therapy
Patients with TI are generally transfusion independent. They may 
require blood transfusions during certain clinical situations, such 
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as pregnancy, surgery or infection.[28] Selected patients may also be 
instituted on a more regular transfusion regimen for the primary 
or secondary prevention of specific clinical complications, such as 
pulmonary hypertension, thromboembolic events, leg ulcers and 
extramedullary haematopoiesis.[29]
Iron chelation
Iron overload in TI results from increased intestinal iron absorption 
as a result of chronic hypoxia. Serum ferritin levels underestimate 
the degree of iron overload in NTDT,[30,31] but are nonetheless still a 
useful test to guide chelation therapy in resource-constrained settings 
where MRI may not be available. Ferritin levels should be monitored 
3-monthly, starting at the age of 10  years, and chelation therapy 
instituted or interrupted at levels of >800   μg/L and <300  μg/L, 
respectively). Based on available evidence, DFX is currently the only 
approved iron chelator for use in NTDT.[29,32] 
Modulation of HbF
Hydroxyurea has been shown to be safe and effective in reducing 
transfusion requirements in patients with TI. While HbF inducers in 
general appear promising, larger randomised and controlled trials are 
needed before their use in TI is widely advocated.[33]
Stem cell transplantation
Stem cell transplantation is rarely performed in TI, and is reserved for 
those patients who develop transfusion dependency.[34,35]
Novel therapies
Many targeted therapies (discussed above) show promise in the 
future management of TI, and may be considered for use where it is 
cost-effective.[28]
Thalassaemia minor
TM is usually asymptomatic and characterised by a borderline or mild 
anaemia and thalassaemic red cell indices (microcytosis, hypochromia, 
elevated red cell count and Mentzer index (MCV/RCC ratio) <13. It 
must be differentiated from iron deficiency anaemia (IDA).
β-thalassaemia minor
The HbA2 level is typically raised, but may be masked by co-existing 
IDA (as IDA decreases the HbA2 level). In such individuals, the IDA 
should be treated prior to Hb electrophoresis.
Premarital and prenatal counselling are important in β-thalassaemia 
minor. If the partner also has β-thalassaemia minor, there is a 25% 
chance of a child born having MT.
No specific treatment is required for individuals with isolated 
β-thalassaemia minor.
Alpha thalassaemia minor 
Alpha thalassaemia minor (deletion or inactivation of 1 or 2 α globin 
genes) is usually asymptomatic. In contrast to β-thalassaemia minor, 
the HbA2 level is normal or borderline low, and the diagnosis is 
suspected upon exclusion of other causes of a microcytic anaemia. 
DNA analysis may be employed in instances where confirmation 
is necessary, such as in prenatal testing. No specific treatment is 
required for individuals with isolated α-thalassaemia minor. 
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